OncoSec Medical Inc (NASDAQ: ONCS) released some big news this morning. The company announced through a press release that it presented an overview of the comprehensive immune monitoring data from the Phase 3 clinical trial surrounding ImmunoPulse®. Here’s what we saw from the release…
ONCS Presents Clinical Data
As mentioned above, OncoSec Medical has presented an overview of the comprehensive immune monitoring data from it’s Phase 2 investigator-sponsored clinical trial. The trial was led by the University of California, San Francisco, and the presentation was held at the 2nd World Congress on Electroporation and Pulst Electric Fields In Biology, Medicine and Food & Environmental Technologies in Norfolk, VA. The clinical trial the data came from looked into the combination of ImmunoPulse® IL-12 and the approved anti-PD-1 therapy known as pembrolizumab in patients with unresectable metastatic melanoma and its ability to convert cold to hot tumors. In a statement, Punit Dhillon, CEO and President at ONCS, had the following to offer:
“These data support our planned phase 2b registration-directed trial, PISCES, which is designed to demonstrate that the combination of ImmunoPulse® IL-12 and pembrolizumab provides an opportunity to address the resistance to andi-PD-1 therapy in the melanoma patient population… Patients with metastatic melanoma who are progressing or have progressed on anti-PD-1 therapy have limited treatment options and we look forward to presenting further data from our recently completed trials at a future medical conference later this year.”
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on ONCS. In particular, we’re interested in following the ongoing work surrounding ImmunoPulse®. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!